Published online Sep 15, 2024. doi: 10.4251/wjgo.v16.i9.3771
Revised: May 22, 2024
Accepted: June 6, 2024
Published online: September 15, 2024
Processing time: 149 Days and 23 Hours
The microbiota is strongly association with cancer. Studies have shown significant differences in the gastric microbiota between patients with gastric cancer (GC) patients and noncancer patients, suggesting that the microbiota may play a role in the development of GC. Although Helicobacter pylori (H. pylori) infection is widely recognized as a primary risk factor for GC, recent studies based on microbiota sequencing technology have revealed that non-H. pylori microbes also have a significant impact on GC. A recent study discovered that Streptococcus anginosus
Core Tip: Advanced gastric cancer has a very poor prognosis at this stage. Early diagnosis and treatment of precancerous lesions of gastric cancer (PLGC) still need further research. Studies of the microbiota associated with PLGC have found that Streptococcus anginosus (S. anginosus) plays an important role in their development. We explore the mechanism of S. anginosus in PLGC and consider its inclusion in the diagnosis and treatment of PLGC.
- Citation: Qian ST, Zhao HY, Xie FF, Liu QS, Cai DL. Streptococcus anginosus in the development and treatment of precancerous lesions of gastric cancer. World J Gastrointest Oncol 2024; 16(9): 3771-3780
- URL: https://www.wjgnet.com/1948-5204/full/v16/i9/3771.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i9.3771
Gastric cancer (GC) is a prevalent form of cancer, ranking fifth in terms of frequency worldwide and third in terms of cancer-related deaths[1]. Risk factors include Helicobacter pylori (H. pylori) infection, age, high salt intake, and a diet low in fruits and vegetables. The median survival rate of advanced GC (AGC) is less than 12 months. Therefore, early diagnosis and timely treatment are the only effective strategies[2]. GC is typically diagnosed histologically following endoscopic biopsy, with staging methods including computed tomography (CT), ultrasound endoscopy, positron emission tomography (PET), and laparoscopy. Pathology-based stages of atrophy, intestinal epithelial hyperplasia, and heterogeneous hyperplasia are collectively referred to as precancerous lesions of GC (PLGC).
Numerous studies have demonstrated a substantial correlation between the microbiota and GC. Notable disparities in the gastric microbiota of GC patients compared to those without suggest that microbiota may play a role in GC development[3]. While H. pylori infection is acknowledged as a primary risk factor, non-H. pylori microorganisms also exert significant influence. Research indicates that the oral microbiota, exemplified by Streptococcus anginosus, contributes to the onset of gastrointestinal cancers through modulation of metabolic pathways and carcinogenic induction[4]. Furthermore, viruses such as Epstein-Barr virus (EBV) and fungi like Candida albicans (C. albicans) are recognized for their impact on gastric mucosal carcinogenesis. In contrast, the bacterial community was predominantly composed of five principal phyla: Thick-walled bacteria, Anaplasma, Aspergillus, Actinobacteria, and Clostridia[5].
Recent research has extensively explored the influence of oral microbiota on the progression of GC. A comparative analysis of gene sequencing from oral samples and gastric sinus mucosal samples revealed a significant enrichment of S. anginosus in intestinal epithelialized mucosal samples, with [odds ratios (ORs) = 1.29-1.50, P = 0.004-0.01][6]. Furthermore, another study demonstrated that an infection by S. anginosus spontaneously triggers chronic inflammation, atrophy, mucus chemotaxis, and heterogeneous hyperplasia, thereby facilitating the development of PLGC[7]. The advent of modern molecular diagnostic techniques such as polymerase chain reaction (PCR), genetic testing, and ultrasensitive chromosomal aneuploidy detection now allows for the specific detection of PLGC through the labeling of S. anginosus.
This article provides a succinct overview of the current state of research on PLGC, while also investigating potential correlations between S. anginosus and PLGC. To enhance the efficacy of PLGC treatment, it is suggested that emphasis should be placed on the prevention, diagnosis, and treatment of S. anginosus. This focus could potentially inspire novel ideas and strategies.
PLGC are a series of changes that occur in the middle of the progression from normal chronic gastritis to GC. It is recognized by experts that pre-cancerous stages of GC encompass mucosal atrophic lesions, intestinal epithelial hyperplasia, and heteroplasia. The progression of the heteroplasia stage corresponds to early GC (EGC)[8]. The 5-year survival rate for AGC is less than 20%, while the 5-year survival rate for EGC can be 90%-95%[9]. The advancement of ultrasound, CT, magnetic resonance imaging (MRI), PET, PET/CT, PET/MRI, and gastroscopy has led to a gradual increase in the detection rate of PLGC[10]. Clinical tests for gastric evaluation include barium meal of the digestive tract, enhanced CT of the abdomen, and gastroscopy. However, at the PLGC stage, the gastric mucosal surface vascularity may remain dense and regular, accompanied by deeper fibrous connective tissue and less pronounced mucosal manifestations. This complexity makes it challenging to assess using gastric barium meal radiography[11]. Enhanced CT of the abdomen does not reveal significant early changes in the gastric mucosa and has low sensitivity[12]. PET is highly sensitive, but costly and radioactive, and incorporated into routine examination programs[13]. Consequently, gastroscopy with biopsy has emerged as the preferred method for diagnosis and treatment. The adoption of tools such as magnified gastroscopy, Near-Infrared Biometry, and staining techniques have elevated the detection rate of EGC[14,15]. Nonetheless, the primary challenge in diagnosing PLGC lies in identifying the challenging-to-spot early precancerous mucosa and implementing routine gastroscopic screening[16,17].
Correa's cascade is frequently employed to depict the progression of PLGC, typically represented as inflammation-atrophy-metaplasia-dysplasia-carcinoma[18,19]. Typically, this process can be segmented into the following stages:
Chronic non-atrophic gastritis (also known as chronic superficial gastritis): This is the early stage of PLGC, mainly manifested as chronic inflammation of gastric mucosa. Gastroscopy can see the mucosa red and white, edema, congestion, erosion, etc. There may also be gastric mucosal roughness, erythema, hemorrhagic spots, oozing and other manifestations. There is usually no obvious atrophy or intestinal epithelial hyperplasia[20,21].
Chronic atrophic gastritis (CAG): In this stage, atrophy of the gastric mucosa occurs, gastric glands are reduced and thinned, which is the key stage of PLGC, most of which are caused by H. pylori infection or autoimmunity. Typical endoscopic features include pale, exfoliative changes in the gastric mucosa, increased visibility of the vascular system due to thinning of the gastric mucosa, loss of the gastric folds, and small, dark-red reticulated blood vessels, and larger blue dendritic veins[22-24].
Gastric mucosal intestinal epithelialization: On the basis of CAG, the gastric mucosal epithelium is transformed into small or large intestinal mucosal epithelial tissue, which is called intestinal epithelialization/intestinalization. Gastroscopy reveals small yellowish or white nodules in the gastric mucosa, which show fluffy or flattened punctate and scaly changes. Pigmented gastroscopy shows light blue cristae and white opaque fields. intestinal epithelialization is an important hallmark of PLGC, which can be categorized into mild, moderate, and severe grades based on the degree and extent of intestinalization[25-28].
Dysplasia (atypical hyperplasia, intraepithelial neoplasia): On the basis of intestinalization, the epithelial cells of gastric mucosa show heteroplasia, i.e., there are abnormalities in the shape, size and arrangement of the cells, which is a direct precursor of GC. Dysplasia can also be categorized into mild, moderate and severe. Gastroscopic manifestations often show mild ectodermal hyperplasia as mild irregularity in the ductal structure, moderate as irregularity in the ductal structure and branching, and severe as disorganization of the ductal structure, with different sizes and shapes. Severe dysplasia is indistinguishable from EGC, and surgical treatment is often advocated[29-31].
The staging of PLGC is not absolute, and different pathologists will have different grading criteria. In addition, the development of PLGC is not linear. Some lesions may remain at a certain stage for a long time, while others may rapidly develop into GC. Consequently, the diagnosis and treatment of PLGC necessitate consideration of multiple factors, including the patient's medical history, clinical manifestations, endoscopic findings, and pathological results.
General management: Patients are advised to modify their dietary structure, avoid spicy, stimulating, raw and cold foods, eat more fresh vegetables and fruits, and try not to eat pickled foods and foods with high nitrite content. Additionally, to quit smoking and drinking, and avoid taking drugs that have damage to the gastric mucosa, such as aspirin. Maintain emotional stability, avoid overwork and late nights, and ensure adequate sleep[32].
Drug therapy: For gastric mucosal inflammation and atrophy, proton pump inhibitors (e.g., omeprazole, lansoprazole,
Surgery: If the gastric precancerous lesion has progressed to the stage of heterogeneous hyperplasia or EGC, surgical treatment needs to be considered. Surgical methods include minimally invasive procedures such as endoscopic mucosal resection and endoscopic mucosal dissection, as well as traditional surgical methods. The optimal surgical strategy must be determined based on the unique circumstances of each patient[18,35].
The microbiota is found throughout our body and the environment in which we live. The strong acidic environment of the stomach has long been widely believed to be unfavorable to the microbiota until H. pylori was discovered and the relationship between stomach-related diseases and microorganisms began to be studied[36]. Due to advances in PCR technology and macrogenomics it has been confirmed that the stomach contains a robust microbiota. As a result, studies on the relationship between gastric microbiota and PLGC have begun to increase[37]. A summary can be found in Table 1.
Microorganisms | Primary site | Potential mechanism | Ref. |
Helicobacter pylori | Gastrointestinal tract, oral | Cytotoxin-associated gene A and vacuolar cytotoxin A cause DNA damage. increased genetic instability leads to mutations | Salvatori et al[71] |
Malfertheiner et al[72] | |||
Streptococcus Anginosus | Oral, nasopharyngeal, gastrointestinal tract, vaginal | The streptococcal surface protein TMPC interacts with ANXA2-mediated attachment and colonization. Spontaneously induces progressive chronic gastritis, atrophy, heterotrophic hyperplasia | Fu et al[73] |
Stasiewicz and Karpiński[74] | |||
EBV | Oropharynx, blood, lymphatic system and other tissues and organs | Viral proteins inducing methylation, regulating host gene expression and malignant transformation | Yang et al[75] |
EBV driving DNA hypermethylation, frequent PIK3CA mutations, and the overexpression of JAK2, PD-L1, and PD-L2 | Iizasa et al[47] | ||
Candida albicans | Skin, oral, gastrointestinal tract | Reduces the diversity and abundance of fungi in the stomach; destroys the mucosal epithelium, produces carcinogens, triggers chronic inflammation, induces Th17 immune responses, among other mechanisms | Yu and Liu[49] |
Zhong et al[50] | |||
Others | Gastrointestinal tract, oral, etc. | Homogeneity and diversity of the gastric microbiota; the inflammatory response; dysbiosis of the gastric microbiota favors invasion and growth of pathogens and disrupts the mucosal barrier | Stewart et al[37] |
Liao et al[76] |
Numerous studies have established H. pylori as a potent risk factor for PLGC, atrophic gastritis, and intestinal epithelial septosis, especially strains carrying the cag pathogenicity island and the cagA oncoprotein. Clinical evidence suggests that H. pylori has an estimated 50% probability of inducing atrophic gastritis or intestinal metaplasia (IM)[38].
H. pylori causes persistent inflammation of the gastric mucosa, constant production of cytokines to recruit immune cells, production of reactive free radicals that may damage host DNA, leading to glandular atrophy and multifocal expansion of enteric areas over time, and a 5 to 90-fold increase in the risk of GC[39].
Microbiota-metabolite interactions are present in the development of GC. During H. pylori infection, cholesterol-rich lipid rafts on the cell membrane may act as adherents to bacterial pathogens or virulence factors. In turn, altered lipid and cholesterol metabolic pathways in the gastric mucosa after H. pylori eradication may be associated with lipid metabolic reprogramming and lipoprotein-mediated cholesterol entry during PLGC[40]. However, the effect of H. pylori eradication on PLGC remains somewhat controversial.
In a study analyzing 16S rRNA genes from 81 gastric mucosa samples, it was found that Peptostreptococcus_OTU16, Streptococcus_OTU68, Parvimonas_OTU35, Slackia_OTU174, and Dialister_OTU151 exhibited interactions with GC. The organisms under consideration are believed to correspond to Peptostreptococcus stomatis, S. anginosus, Parvimonas micra, Slackia exigua, and Dialister pneumosintes[41]. The emergence and persistence of gastric atrophy and IM were associated with a distinct cluster of oral bacteria, including Peptostreptococcus, Streptococcus, Parvimonas, Prevotella, Rothia, and Granulicatella[42]. The presence of S. anginosus has been identified in esophageal cancer tissues, albeit less frequently in normal tissues[43]. These bacterial species have also been correlated with inflammatory markers in blood samples, reinforcing the notion that oral bacteria such as S. anginosus might play a role in tumor development[44].
EBV is a ubiquitous γ herpesvirus, mounting evidence suggests its potential etiologic role in GC[45]. EBV-associated GC (EBVaGC) accounts for approximately 10% of all cancer cases and constitutes a distinct clinicopathologic and molecular subtype[46]. EBV is similar to H. pylori by promoting chronic inflammation and increasing tissue damage. Positive cells proliferate after EBV infection, and B lymphocytes in areas of weakened immune surveillance undergo lysogenic infection, causing EBV infection of gastric epithelial cells[47]. New insights into the mechanism of EBVaGC production are thought to include amplification of chr 9p24.1 (JAK/PD-L1), regulation of methylation and cellular autophagy, EBV lytic cycle reactivation, EBV-miRNA, exosomes, and immunosuppression[48]. Specific mechanisms and characterization of cancer genomic profiles need to be further explored.
C. albicans is an opportunistic pathogenic fungus that infects immunocompromised hosts, including precancerous states. C. albicans infection increases host susceptibility to cancers such as oral, gastric, and colorectal cancers[49]. C. albicans produces carcinogenic nitrosamines, induces dysbiosis of mucosal bacterial flora, triggers chronic inflammation (including Th17 cell-mediated immune responses) and promotes invasive infections[50].
In addition to common microorganisms, other microorganisms associated with PLGC include Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria and Fusobacteria. Gastric microbial imbalances associated with GC can be detected regularly in gastric biopsies. Patients with intestinal-type GC contain more Lactobacillus coleohominis and Lachnospiraceae[51]. However, the effect of H. pylori on the microorganisms of the gastric mucosa still cannot be ruled out, with reduced microbial diversity, altered microbial community structure, and possible negative interactions between H. pylori and other microorganisms[52].
S. anginosus, also can be called S. anginosus group (SAG) or Streptococcus milleri group, was isolated and first described by Guthof in 1956 from dental abscesses and other inflammatory lesions of the oral cavity[53]. This is a gram-positive coccobacillus found primarily in the oral cavity, nasopharynx, gastrointestinal tract, and vagina, and can cause invasive pyogenic infections such as abscesses. The SAG comprises three species: S. anginosus, Streptococcus constellatus, and Streptococcus intermedius. There are also subspecies such as Streptococcus pyogenes Willie subspecies and Streptococcus constellatus Viborg subspecies.
S. anginosus is more commonly associated with gastrointestinal and genitourinary tract infections, Streptococcus constellatus has a predisposition to respiratory tract infections, and Streptococcus intermedius is the cause of most head and neck infections and central nervous system infections[54-56].
It has been studied in various systems, with the oral cavity being the most studied aspect of it (Table 2). However, it has a unique mechanism of action in the digestive system.
Primary site | Developing diseases | Mechanism of action | Subsequent effect | Ref. |
Oral | Periodontal abscess | Production of bacteriocins enhances membrane permeability, inhibits the growth of associated species, promotes the development of chronic inflammation and abscesses | Dental periapical abscesses | Fisher and Russell[77] |
OIs | Furuholm et al[78] | |||
Respiratory tract | Lung abscess | Inhalation of oral secretions, direct trauma or surgical bedding, adjacent extension, and hematogenous dissemination | Parapneumonic empyema | Gonzalez et al[79] |
Esophagus | Esophageal cancer | Correlated with GrzB+ and CD8+T-cell infiltration in tumor tissues | Esophageal squamous cell carcinoma; Barrett's esophagus | Lv et al[80] |
Wu et al[81] | ||||
Stomach | Gastric cancer | Spontaneously induced chronic inflammation, atrophy, mucus chemotaxis, and heterogeneous hyperplasia of the gastric mucosa | PLGC | Yang[7] |
Zhou et al[82] | ||||
Intestinal tract | Colorectal cancer | Loss of integrity of the blood mucosal barrier forms pus-filled and infected | Adenocarcinoma of the colon | Rawla et al[83] |
Liver | Liver abscess | Causes localized suppurative inflammation destroying hepatocytes and surrounding tissues | PLA | Pilarczyk-Zurek et al[55] |
Morii et al[84] | ||||
Genitourinary tract | Genitourinary infections | Invades the bloodstream following urinary tract infections; causes lysis of vaginal epithelial cells | Urinary tract infection | Wu and Zheng[85] |
Aerobic vaginitis | Tao et al[86] | |||
Hearts | Pericarditis, endocarditis | Hematogenous dissemination from distant organs | Bacterial pericarditis; infective endocarditis | Finn et al[87] |
Cerebrum | Brain abscess, meningitis | Continuous venous dissemination or hematogenous dissemination from a distant site; invasive pyogenic infection | Subdural hemorrhage | Esplin et al[88] |
Intracranial subdural abscess; hydrocephalus | Sakurai et al[89] |
S. anginosus causes Lemierre's syndrome, which promotes the cancerous process by inducing inflammation[57]. Sasaki et al[43] found S. anginosus DNA sequences in samples from esophageal dysplasia, esophageal carcinoma and gastric carcinoma tissues, whereas the noncancerous portion of the esophagus only 7% of cases[43].
The study by Meddings et al[58] showed that the most common microorganisms isolated from pus in patients with culture-positive pyogenic liver abscesses were Streptococcus spp. (29.5%)[58]. A retrospective study of patients with pyogenic liver abscesses showed that the most common causative pathogens were SAG (25%), Klebsiella pneumoniae (21%) and Escherichia coli (16%)[59].
SAG has been shown to cross the mucosal barrier of the gastrointestinal tract and metastasize to extragastrointestinal organs, resulting in abdominal implantation. A study by Wenzler et al[60] found that 18 cases (53% of 34 patients) were the source of gastrointestinal bacteremia, which caused tumors[60].
The mechanism underlying the role of S. anginosus in the digestive system remains an area of ongoing research. Existing studies have provided some explanation of the mechanism of S. anginosus action in PLGC by genomic analysis of gastric mucosal samples at different stages of GC[44].
S. anginosus has a marked ability to adapt to pH 3-5 environments and can survive in slightly acidic environments[61]. Streptococcal infections are divided into three main phases: Adherence, invasion, and colonization of host tissues. Streptococcus colonization disarms neutrophil extracellular traps consisting of chromosomal DNA and bactericidal proteins, which are released by neutrophils upon stimulation, i.e., interleukin-8 or hydrogen peroxide, to stimulate the inflammatory response to occur. S. anginosus was demonstrated to undergo a rapid acute inflammatory response in the gastric mucosa of mice, stimulating upregulation of pro-inflammatory cytokines, including Ccl20 and Ccl8, leading to severe gastritis or persistent chronic gastritis[62]. The chronic inflammatory response leads to progressive gastric carcinogenesis, including mural cell atrophy, mucoid chemotaxis, and heterogeneous hyperplasia.
The virulence surface factor TMPC of streptococci can bind to ANXA2 on gastric epithelial cells to trigger downstream activation of bacterial attachment, invasion, and oncogenic MAPK signaling[63]. The MAPK pathway activates three subfamilies involved in GC progression: ERK, JNK, and p-38 kinase. Meanwhile, S. anginosus impairs gastric barrier function, as evidenced by a time-dependent decrease in the expression of tight junction markers CLDN18, OCLN, and ZO-1, whose disruption is a hallmark of gastric tumorigenesis[64].
Pre-cancerous infections of S. anginosus may inhibit the growth and colonization of other microorganisms by competing for nutrients, space, or secretion of antimicrobial substances, leading to elevated gastric pH[65]. A significant increase in streptococci in the stomach with gastric sinusitis was accompanied by a decrease in the Aspergillus phylum and an increase in the thick-walled phylum[66]. S. anginosus is a sulfate-reducing bacterium involved in colonic sulfur metabolism, and the differences in bacterial abundance comparing cancerous and noncancerous tissues may indicate that ecological dysregulation occurs in the environment of the PLGC[41]. Thus, gastric flora dysbiosis and microenvironmental disturbances caused by S. anginosus infections are also possible causes of PLGC.
There is no particularly sophisticated test for S. anginosus, which can only be detected by microbial markers using modern novel molecular diagnostic techniques. And there is no definitive diagnosis of PLGC, which is often confirmed by pathology. Therefore, we hope to achieve the detection and treatment of PLGC by detecting and treating S. anginosus.
There are no standard guidelines for the treatment of S. anginosus, and it is mostly controlled and eradicated by dietary changes and medication.
The effect of dietary therapy on S. anginosus remains incompletely elucidated, mainly in the form of dietary adjustments and abstinence from fatty, sweet, and thick flavors, which help patients to improve their immunity and promote PLGC recovery. Dietary modifications do not directly kill S. anginosus and need to be combined with antibiotics or other treatments.
S. anginosus is usually sensitive to penicillin. The minimal inhibitory concentration (MIC) of penicillin G for S. anginosus ranges between 0.03 and 0.06 μg/mL. The mechanism is the down-regulation of penicillin-binding proteins during the stationary phase of growth, resulting in penicillin target deficiency. In addition to β-lactams, glycopeptides, daptomycin, and linezolid have been shown to be useful in the treatment of S. anginosus[67].
In some cases S. anginosus may be relatively insensitive to penicillin, with a MIC of more than 0.1 μg/mL. There are also studies confirming that all SAG are susceptible to vancomycin. Therefore, initial treatment with vancomycin followed by establishing the MIC for penicillin is a safer approach. Beta-lactam antibiotics remain the antibiotic of choice based on penicillin susceptibility testing[68].
Combination therapy with broad-spectrum antibiotics such as ampicillin, gentamicin, and metronidazole has also been suggested as initial empiric therapy. 134/156 (86%) children discharged from the hospital on oral antibiotics were given amoxicillin, amoxicillin clavulanate, or the first-generation cephalosporin cefadroxil, with fair results[69].
However, the use of antibiotics should be accompanied by attention to the effects of the antibiotics themselves on the gastric mucosa. Antibiotics may cause insufficiency of prostaglandin E, which maintains normal regeneration of the mucosa, through nonspecific inhibition of cyclooxygenase activity. Insufficient prostaglandin E may be detrimental to epithelial cell repair, thereby triggering gastric mucosal injury and exacerbating the progression of PLGC[70].
There is no standardized treatment criteria at this stage, and considerable research is still needed at a later stage to confirm and establish a standard accepted normative treatment modality. Meanwhile the effect of some novel modalities, such as fecal transplantation, on gastric mucosal damage caused by S. anginosus is still under study.
With the improvement of living standards and the popularization of gastroscopy, the incidence of GC has increased significantly, but the mortality rate has not decreased. PLGC is a critical period. Most microorganisms affect the development of PLGC. The effect of H. pylori is limited, and other microbiota, such as S. anginosus, promote the development of PLGC with new research progress. Therefore, we synthesize the relationship between microorganisms and PLGC, especially the possible mechanisms by which S. anginosus causes PLGC. It was found that eradication of S. anginosus infections by adopting a positive diet and antibiotic treatment is expected to prevent PLGC. However, because of the few studies, a large number of animal studies and clinical trials are still needed to confirm the association and the specific mechanism of action.
We gratefully acknowledge the kind cooperation of all authors in the preparation of this paper.
1. | Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635-648. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1150] [Cited by in F6Publishing: 2100] [Article Influence: 525.0] [Reference Citation Analysis (0)] |
2. | Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. Int J Mol Sci. 2020;21. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 486] [Cited by in F6Publishing: 626] [Article Influence: 156.5] [Reference Citation Analysis (0)] |
3. | Bessède E, Mégraud F. Microbiota and gastric cancer. Semin Cancer Biol. 2022;86:11-17. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 6] [Cited by in F6Publishing: 36] [Article Influence: 18.0] [Reference Citation Analysis (0)] |
4. | Bakhti SZ, Latifi-Navid S. Oral microbiota and Helicobacter pylori in gastric carcinogenesis: what do we know and where next? BMC Microbiol. 2021;21:71. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 10.0] [Reference Citation Analysis (0)] |
5. | Wang Y, Han W, Wang N, Han M, Ban M, Dai J, Dong Y, Sun T, Xu J. The role of microbiota in the development and treatment of gastric cancer. Front Oncol. 2023;13:1224669. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
6. | Wu F, Yang L, Hao Y, Zhou B, Hu J, Yang Y, Bedi S, Sanichar NG, Cheng C, Perez-Perez G, Tseng W, Tseng W, Tseng M, Francois F, Khan AR, Li Y, Blaser MJ, Shu XO, Long J, Li H, Pei Z, Chen Y. Oral and gastric microbiome in relation to gastric intestinal metaplasia. Int J Cancer. 2022;150:928-940. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 12] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis (0)] |
7. | Yang HJ. [Gastric Cancer and Gastric Microbiome]. Korean J Gastroenterol. 2023;81:235-242. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
8. | Gullo I, Grillo F, Mastracci L, Vanoli A, Carneiro F, Saragoni L, Limarzi F, Ferro J, Parente P, Fassan M. Precancerous lesions of the stomach, gastric cancer and hereditary gastric cancer syndromes. Pathologica. 2020;112:166-185. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 11.8] [Reference Citation Analysis (0)] |
9. | Zhang S, Shen Y, Liu H, Zhu D, Fang J, Pan H, Liu W. Inflammatory microenvironment in gastric premalignant lesions: implication and application. Front Immunol. 2023;14:1297101. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
10. | Zhang Y, Yu J. The role of MRI in the diagnosis and treatment of gastric cancer. Diagn Interv Radiol. 2020;26:176-182. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 19] [Cited by in F6Publishing: 41] [Article Influence: 10.3] [Reference Citation Analysis (0)] |
11. | Liang P, Zhu B, Ren XC, Lyu D, Cheng M, Gao JB. Gastric morphological type: A supplementary addition for the evaluation of gastric cancer. Oncol Lett. 2023;25:178. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
12. | Huang W, Wang C, Wang Y, Yu Z, Wang S, Yang J, Lu S, Zhou C, Wu E, Chen J. Predicting malnutrition in gastric cancer patients using computed tomography(CT) deep learning features and clinical data. Clin Nutr. 2024;43:881-891. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Reference Citation Analysis (0)] |
13. | Liu L, Zhong J, Zhang Z, Ye X, Wang X, Liu S, Zhang Z. Preclinical study and first-in-human imaging of [(18)F]FAP-2286, and comparison with 2-[(18)F]FDG PET/CT in various cancer patients. Eur J Nucl Med Mol Imaging. 2024;. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Reference Citation Analysis (0)] |
14. | Cho JH, Jin SY, Park S. Carbon footprint and cost reduction by endoscopic grading of gastric intestinal metaplasia using narrow-band imaging. J Gastroenterol Hepatol. 2024;39:942-948. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
15. | Tokai Y, Horiuchi Y, Yamamoto N, Namikawa K, Yoshimizu S, Ishiyama A, Yoshio T, Hirasawa T, Fujisaki J. Effect of Helicobacter pylori eradication evaluated using magnifying endoscopy with narrow-band imaging in mixed-type early gastric Cancer. BMC Gastroenterol. 2023;23:425. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
16. | Chen X, Ze Y, Yi W, Yang Y, Sun R, Tu H. Barriers to upper gastrointestinal screening among the general population in high-prevalence areas: a cross-sectional study. JBI Evid Implement. 2024;22:218-227. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
17. | Emura F. Missed gastric cancer: tackling the elephant in the room. Gastrointest Endosc. 2023;98:744-746. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
18. | Conti CB, Agnesi S, Scaravaglio M, Masseria P, Dinelli ME, Oldani M, Uggeri F. Early Gastric Cancer: Update on Prevention, Diagnosis and Treatment. Int J Environ Res Public Health. 2023;20. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 21] [Article Influence: 21.0] [Reference Citation Analysis (0)] |
19. | Guo C, Wan L, Li C, Wen Y, Pan H, Zhao M, Wang J, Ma X, Nian Q, Tang J, Zeng J. Natural products for gastric carcinoma prevention and treatment: Focus on their antioxidant stress actions in the Correa's cascade. Phytomedicine. 2024;123:155253. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
20. | Privitera G, Williams JJ, De Salvo C. The Importance of Th2 Immune Responses in Mediating the Progression of Gastritis-Associated Metaplasia to Gastric Cancer. Cancers (Basel). 2024;16. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
21. | Jaroenlapnopparat A, Bhatia K, Coban S. Inflammation and Gastric Cancer. Diseases. 2022;10. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 11] [Reference Citation Analysis (1)] |
22. | Lim NR, Chung WC. Helicobacter pylori-associated Chronic Atrophic Gastritis and Progression of Gastric Carcinogenesis. Korean J Gastroenterol. 2023;82:171-179. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 2] [Reference Citation Analysis (0)] |
23. | Shah SC, Piazuelo MB, Kuipers EJ, Li D. AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review. Gastroenterology. 2021;161:1325-1332.e7. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 58] [Cited by in F6Publishing: 150] [Article Influence: 50.0] [Reference Citation Analysis (0)] |
24. | Delgado-Guillena P, Velamazan-Sandalinas R, Jiménez Sánchez J, Fuentes-Valenzuela E, García-Morales N, Cuatrecasas M, Jimeno M, Moreira L, Albéniz E. History and clinical guidelines for chronic atrophic gastritis and the assessment of gastric cancer risk. Gastroenterol Hepatol. 2023;46:727-731. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 1] [Reference Citation Analysis (0)] |
25. | Zhang C, Jiao X, Shen L. From intestinal metaplasia to gastric cancer: Witnessing the rise of evil over time and space. Cancer Cell. 2023;41:2011-2013. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
26. | Tong QY, Pang MJ, Hu XH, Huang XZ, Sun JX, Wang XY, Burclaff J, Mills JC, Wang ZN, Miao ZF. Gastric intestinal metaplasia: progress and remaining challenges. J Gastroenterol. 2024;59:285-301. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
27. | Khazaaleh S, Alomari M, Rashid MU, Castaneda D, Castro FJ. Gastric intestinal metaplasia and gastric cancer prevention: Watchful waiting. Cleve Clin J Med. 2024;91:33-39. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
28. | Tjandra D, Busuttil RA, Boussioutas A. Gastric Intestinal Metaplasia: Challenges and the Opportunity for Precision Prevention. Cancers (Basel). 2023;15. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
29. | Kim SJ, Choi CW, Kang DH, Kim HW, Park SB. Comparison of biannual and annual endoscopic gastric cancer surveillance after endoscopic resection. Surg Endosc. 2022;36:1806-1813. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
30. | Min J, Zhang C, Bliton RJ, Caldwell B, Caplan L, Presentation KS, Park DJ, Kong SH, Lee HS, Washington MK, Kim WH, Lau KS, Magness ST, Lee HJ, Yang HK, Goldenring JR, Choi E. Dysplastic Stem Cell Plasticity Functions as a Driving Force for Neoplastic Transformation of Precancerous Gastric Mucosa. Gastroenterology. 2022;163:875-890. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis (0)] |
31. | Ushiku T, Lauwers GY. Pathology and Clinical Relevance of Gastric Epithelial Dysplasia. Gastroenterol Clin North Am. 2024;53:39-55. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
32. | Pimentel-Nunes P, Libânio D, Marcos-Pinto R, Areia M, Leja M, Esposito G, Garrido M, Kikuste I, Megraud F, Matysiak-Budnik T, Annibale B, Dumonceau JM, Barros R, Fléjou JF, Carneiro F, van Hooft JE, Kuipers EJ, Dinis-Ribeiro M. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51:365-388. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 432] [Cited by in F6Publishing: 522] [Article Influence: 104.4] [Reference Citation Analysis (0)] |
33. | Wang P, Li P, Chen Y, Li L, Lu Y, Zhou W, Bian L, Zhang B, Yin X, Li J, Chen J, Zhang S, Shi Y, Tang X. Chinese integrated guideline on the management of gastric precancerous conditions and lesions. Chin Med. 2022;17:138. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2] [Reference Citation Analysis (0)] |
34. | Yang L, Li J, Hu Z, Fan X, Cai T, Hengli Zhou, Pan H. A Systematic Review of the Mechanisms Underlying Treatment of Gastric Precancerous Lesions by Traditional Chinese Medicine. Evid Based Complement Alternat Med. 2020;2020:9154738. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis (0)] |
35. | Young E, Philpott H, Singh R. Endoscopic diagnosis and treatment of gastric dysplasia and early cancer: Current evidence and what the future may hold. World J Gastroenterol. 2021;27:5126-5151. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis (3)] |
36. | Sgambato D, Miranda A, Romano L, Romano M. Gut microbiota and gastric disease. Minerva Gastroenterol Dietol. 2017;63:345-354. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis (0)] |
37. | Stewart OA, Wu F, Chen Y. The role of gastric microbiota in gastric cancer. Gut Microbes. 2020;11:1220-1230. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 54] [Cited by in F6Publishing: 96] [Article Influence: 24.0] [Reference Citation Analysis (0)] |
38. | Aumpan N, Mahachai V, Vilaichone RK. Management of Helicobacter pylori infection. JGH Open. 2023;7:3-15. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 11] [Reference Citation Analysis (0)] |
39. | Kumar S, Patel GK, Ghoshal UC. Helicobacter pylori-Induced Inflammation: Possible Factors Modulating the Risk of Gastric Cancer. Pathogens. 2021;10. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 6] [Cited by in F6Publishing: 34] [Article Influence: 11.3] [Reference Citation Analysis (0)] |
40. | Peng L, Guo Y, Gerhard M, Gao JJ, Liu ZC, Mejías-Luque R, Zhang L, Vieth M, Ma JL, Liu WD, Li ZX, Zhou T, Li WQ, You WC, Zhang Y, Pan KF. Metabolite Alterations and Interactions with Microbiota in Helicobacter pylori-Associated Gastric Lesions. Microbiol Spectr. 2023;11:e0534722. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
41. | Coker OO, Dai Z, Nie Y, Zhao G, Cao L, Nakatsu G, Wu WK, Wong SH, Chen Z, Sung JJY, Yu J. Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut. 2018;67:1024-1032. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 304] [Cited by in F6Publishing: 398] [Article Influence: 66.3] [Reference Citation Analysis (0)] |
42. | Sung JJY, Coker OO, Chu E, Szeto CH, Luk STY, Lau HCH, Yu J. Gastric microbes associated with gastric inflammation, atrophy and intestinal metaplasia 1 year after Helicobacter pylori eradication. Gut. 2020;69:1572-1580. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 88] [Cited by in F6Publishing: 131] [Article Influence: 32.8] [Reference Citation Analysis (1)] |
43. | Sasaki H, Ishizuka T, Muto M, Nezu M, Nakanishi Y, Inagaki Y, Watanabe H, Watanabe H, Terada M. Presence of Streptococcus anginosus DNA in esophageal cancer, dysplasia of esophagus, and gastric cancer. Cancer Res. 1998;58:2991-2995. [PubMed] [Cited in This Article: ] |
44. | Kuryłek A, Stasiak M, Kern-Zdanowicz I. Virulence factors of Streptococcus anginosus - a molecular perspective. Front Microbiol. 2022;13:1025136. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis (0)] |
45. | Hirabayashi M, Georges D, Clifford GM, de Martel C. Estimating the Global Burden of Epstein-Barr Virus-Associated Gastric Cancer: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2023;21:922-930.e21. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis (0)] |
46. | Pereira MA, Batista DAM, Ramos MFKP, Cardili L, Ribeiro RRE, Dias AR, Zilberstein B, Ribeiro U Jr, Cecconello I, Alves VAF, Mello ES. Epstein-Barr Virus Positive Gastric Cancer: A Distinct Subtype Candidate for Immunotherapy. J Surg Res. 2021;261:130-138. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis (0)] |
47. | Iizasa H, Kartika AV, Fekadu S, Okada S, Onomura D, Wadi AFAA, Khatun MM, Moe TM, Nishikawa J, Yoshiyama H. Development of Epstein-Barr virus-associated gastric cancer: Infection, inflammation, and oncogenesis. World J Gastroenterol. 2022;28:6249-6257. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis (0)] |
48. | Re V, Brisotto G, Repetto O, De Zorzi M, Caggiari L, Zanussi S, Alessandrini L, Canzonieri V, Miolo G, Puglisi F, Belluco C, Steffan A, Cannizzaro R. Overview of Epstein-Barr-Virus-Associated Gastric Cancer Correlated with Prognostic Classification and Development of Therapeutic Options. Int J Mol Sci. 2020;21. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis (0)] |
49. | Yu D, Liu Z. The research progress in the interaction between Candida albicans and cancers. Front Microbiol. 2022;13:988734. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 12] [Reference Citation Analysis (0)] |
50. | Zhong M, Xiong Y, Zhao J, Gao Z, Ma J, Wu Z, Song Y, Hong X. Candida albicans disorder is associated with gastric carcinogenesis. Theranostics. 2021;11:4945-4956. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 18.3] [Reference Citation Analysis (0)] |
51. | Aviles-Jimenez F, Vazquez-Jimenez F, Medrano-Guzman R, Mantilla A, Torres J. Stomach microbiota composition varies between patients with non-atrophic gastritis and patients with intestinal type of gastric cancer. Sci Rep. 2014;4:4202. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 179] [Cited by in F6Publishing: 237] [Article Influence: 23.7] [Reference Citation Analysis (0)] |
52. | Gunathilake M, Lee J, Choi IJ, Kim YI, Kim J. Association between bacteria other than Helicobacter pylori and the risk of gastric cancer. Helicobacter. 2021;26:e12836. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis (1)] |
53. | Ruoff KL. Streptococcus anginosus ("Streptococcus milleri"): the unrecognized pathogen. Clin Microbiol Rev. 1988;1:102-108. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 164] [Cited by in F6Publishing: 162] [Article Influence: 4.5] [Reference Citation Analysis (0)] |
54. | Jensen A, Hoshino T, Kilian M. Taxonomy of the Anginosus group of the genus Streptococcus and description of Streptococcus anginosus subsp. whileyi subsp. nov. and Streptococcus constellatus subsp. viborgensis subsp. nov. Int J Syst Evol Microbiol. 2013;63:2506-2519. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 4.4] [Reference Citation Analysis (0)] |
55. | Pilarczyk-Zurek M, Sitkiewicz I, Koziel J. The Clinical View on Streptococcus anginosus Group - Opportunistic Pathogens Coming Out of Hiding. Front Microbiol. 2022;13:956677. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis (0)] |
56. | Vulisha AK, Sam R, Nur H, Bhardwaj N, Sirineni S. Aggressive Presentation of Streptococcus constellatus. Cureus. 2021;13:e14534. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis (0)] |
57. | Osman M, Hasan S, Bachuwa G. Oesophageal cancer presenting as Lemierre's syndrome caused by Streptococcus anginosus. BMJ Case Rep. 2017;2017. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis (0)] |
58. | Meddings L, Myers RP, Hubbard J, Shaheen AA, Laupland KB, Dixon E, Coffin C, Kaplan GG. A population-based study of pyogenic liver abscesses in the United States: incidence, mortality, and temporal trends. Am J Gastroenterol. 2010;105:117-124. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 187] [Cited by in F6Publishing: 194] [Article Influence: 13.9] [Reference Citation Analysis (0)] |
59. | Pang TC, Fung T, Samra J, Hugh TJ, Smith RC. Pyogenic liver abscess: an audit of 10 years' experience. World J Gastroenterol. 2011;17:1622-1630. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 107] [Cited by in F6Publishing: 97] [Article Influence: 7.5] [Reference Citation Analysis (1)] |
60. | Wenzler E, Chandrasekaran V, Salvador P, Anwar M, Pancholi P, McGwire BS. Clinical and microbiological outcomes in patients with Streptococcus anginosus group bacteraemia identified through use of a rapid microarray assay. J Med Microbiol. 2015;64:1369-1374. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis (0)] |
61. | Vogel V, Bauer R, Mauerer S, Schiffelholz N, Haupt C, Seibold GM, Fändrich M, Walther P, Spellerberg B. Angicin, a novel bacteriocin of Streptococcus anginosus. Sci Rep. 2021;11:24377. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis (0)] |
62. | Bockerstett KA, Lewis SA, Wolf KJ, Noto CN, Jackson NM, Ford EL, Ahn TH, DiPaolo RJ. Single-cell transcriptional analyses of spasmolytic polypeptide-expressing metaplasia arising from acute drug injury and chronic inflammation in the stomach. Gut. 2020;69:1027-1038. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 30] [Cited by in F6Publishing: 45] [Article Influence: 11.3] [Reference Citation Analysis (0)] |
63. | Abdullah MR, Batuecas MT, Jennert F, Voß F, Westhoff P, Kohler TP, Molina R, Hirschmann S, Lalk M, Hermoso JA, Hammerschmidt S. Crystal Structure and Pathophysiological Role of the Pneumococcal Nucleoside-binding Protein PnrA. J Mol Biol. 2021;433:166723. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis (0)] |
64. | Suzuki K, Sentani K, Tanaka H, Yano T, Suzuki K, Oshima M, Yasui W, Tamura A, Tsukita S. Deficiency of Stomach-Type Claudin-18 in Mice Induces Gastric Tumor Formation Independent of H pylori Infection. Cell Mol Gastroenterol Hepatol. 2019;8:119-142. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis (0)] |
65. | He C, Peng C, Shu X, Wang H, Zhu Z, Ouyang Y, Yang X, Xie C, Hu Y, Li N, Ge Z, Zhu Y, Lu N. Convergent dysbiosis of gastric mucosa and fluid microbiome during stomach carcinogenesis. Gastric Cancer. 2022;25:837-849. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 16] [Reference Citation Analysis (0)] |
66. | Nardone G, Compare D. The human gastric microbiota: Is it time to rethink the pathogenesis of stomach diseases? United European Gastroenterol J. 2015;3:255-260. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 129] [Cited by in F6Publishing: 151] [Article Influence: 16.8] [Reference Citation Analysis (0)] |
67. | Baracco GJ. Infections Caused by Group C and G Streptococcus (Streptococcus dysgalactiae subsp. equisimilis and Others): Epidemiological and Clinical Aspects. Microbiol Spectr. 2019;7. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 16] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis (0)] |
68. | Al Majid F, Aldrees A, Barry M, Binkhamis K, Allam A, Almohaya A. Streptococcus anginosus group infections: Management and outcome at a tertiary care hospital. J Infect Public Health. 2020;13:1749-1754. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis (0)] |
69. | Ismail K, Hughes I, Moloney S, Grimwood K. Streptococcus anginosus group infections in hospitalised children and young people. J Paediatr Child Health. 2022;58:809-814. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
70. | Ibrahim NA, Elmorshedy KE, Radwan DA, Buabeid MA. The impact of oral ciprofloxacin on the structure and functions of rat gastric mucosa. Saudi J Biol Sci. 2022;29:2187-2198. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis (0)] |
71. | Salvatori S, Marafini I, Laudisi F, Monteleone G, Stolfi C. Helicobacter pylori and Gastric Cancer: Pathogenetic Mechanisms. Int J Mol Sci. 2023;24. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 37] [Reference Citation Analysis (0)] |
72. | Malfertheiner P, Camargo MC, El-Omar E, Liou JM, Peek R, Schulz C, Smith SI, Suerbaum S. Helicobacter pylori infection. Nat Rev Dis Primers. 2023;9:19. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 161] [Reference Citation Analysis (0)] |
73. | Fu K, Cheung AHK, Wong CC, Liu W, Zhou Y, Wang F, Huang P, Yuan K, Coker OO, Pan Y, Chen D, Lam NM, Gao M, Zhang X, Huang H, To KF, Sung JJY, Yu J. Streptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in mice. Cell. 2024;187:882-896.e17. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis (0)] |
74. | Stasiewicz M, Karpiński TM. The oral microbiota and its role in carcinogenesis. Semin Cancer Biol. 2022;86:633-642. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 12] [Cited by in F6Publishing: 85] [Article Influence: 42.5] [Reference Citation Analysis (1)] |
75. | Yang J, Liu Z, Zeng B, Hu G, Gan R. Epstein-Barr virus-associated gastric cancer: A distinct subtype. Cancer Lett. 2020;495:191-199. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 20] [Cited by in F6Publishing: 58] [Article Influence: 14.5] [Reference Citation Analysis (0)] |
76. | Liao O, Ye G, Du Q, Ye J. Gastric microbiota in gastric cancer and precancerous stages: Mechanisms of carcinogenesis and clinical value. Helicobacter. 2023;28:e12964. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
77. | Fisher LE, Russell RR. The isolation and characterization of milleri group streptococci from dental periapical abscesses. J Dent Res. 1993;72:1191-1193. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 1.1] [Reference Citation Analysis (0)] |
78. | Furuholm J, Uittamo J, Rautaporras N, Välimaa H, Snäll J. Streptococcus anginosus: a stealthy villain in deep odontogenic abscesses. Odontology. 2023;111:522-530. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
79. | Gonzalez LM, Nessa L, Sanivarapu R, Rangaswamy B, Rojo L. Streptococcus anginosus Lung Abscess With Complicated Parapneumonic Empyema. Cureus. 2023;15:e37506. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 1] [Reference Citation Analysis (0)] |
80. | Lv J, Guo L, Liu JJ, Zhao HP, Zhang J, Wang JH. Alteration of the esophageal microbiota in Barrett's esophagus and esophageal adenocarcinoma. World J Gastroenterol. 2019;25:2149-2161. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 63] [Article Influence: 12.6] [Reference Citation Analysis (2)] |
81. | Wu H, Leng X, Liu Q, Mao T, Jiang T, Liu Y, Li F, Cao C, Fan J, Chen L, Chen Y, Yao Q, Lu S, Liang R, Hu L, Liu M, Wan Y, Li Z, Peng J, Luo Q, Zhou H, Yin J, Xu K, Lan M, Peng X, Lan H, Li G, Han Y, Zhang X, Xiao ZJ, Lang J, Wang G, Xu C. Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma. Cancer Res. 2023;83:3131-3144. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis (0)] |
82. | Zhou CB, Pan SY, Jin P, Deng JW, Xue JH, Ma XY, Xie YH, Cao H, Liu Q, Xie WF, Zou XP, Sheng JQ, Wang BM, Wang H, Ren JL, Liu SD, Sun YW, Meng XJ, Zhao G, Chen JX, Cui Y, Wang PQ, Guo HM, Yang L, Chen X, Ding J, Yang XN, Wang XK, Qian AH, Hou LD, Wang Z, Chen YX, Fang JY. Fecal Signatures of Streptococcus anginosus and Streptococcus constellatus for Noninvasive Screening and Early Warning of Gastric Cancer. Gastroenterology. 2022;162:1933-1947.e18. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 8] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis (0)] |
83. | Rawla P, Vellipuram AR, Bandaru SS, Pradeep Raj J. Colon Carcinoma Presenting as Streptococcus anginosus Bacteremia and Liver Abscess. Gastroenterology Res. 2017;10:376-379. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis (0)] |
84. | Morii K, Fujiwara S, Nakamura S, Okushin H. Streptococcus Anginosus Group-associated Pyogenic Liver Abscess. Intern Med. 2018;57:2271-2272. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis (0)] |
85. | Wu H, Zheng R. Splenic abscess caused by Streptococcus anginosus bacteremia secondary to urinary tract infection: a case report and literature review. Open Med (Wars). 2020;15:997-1002. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis (0)] |
86. | Tao Z, Zhang L, Zhang Q, Lv T, Chen R, Wang L, Huang Z, Hu L, Liao Q. The Pathogenesis Of Streptococcus anginosus In Aerobic Vaginitis. Infect Drug Resist. 2019;12:3745-3754. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 12] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis (0)] |
87. | Finn T, Schattner A, Dubin I, Cohen R. Streptococcus anginosus endocarditis and multiple liver abscesses in a splenectomised patient. BMJ Case Rep. 2018;2018. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis (0)] |
88. | Esplin N, Stelzer JW, All S, Kumar S, Ghaffar E, Ali S. A Case of Streptococcus anginosus Brain Abscess Caused by Contiguous Spread from Sinusitis in an Immunocompetent Patient. Cureus. 2017;9:e1745. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
89. | Sakurai M, Watari T, Nakamura I, Azuma K, Homma H. Acute Hydrocephalus Associated with Streptococcus anginosus Meningitis. Eur J Case Rep Intern Med. 2022;9:003653. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |